Literature DB >> 8154949

The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.

W D Kniffin1, J A Baron, J Barrett, J D Birkmeyer, F A Anderson.   

Abstract

BACKGROUND: There are no studies that define the basic epidemiology of pulmonary embolism (PE) and deep venous thrombosis (DVT) in the elderly. This project was undertaken to provide that information.
METHODS: We obtained all Medicare claims during the period 1986 through 1989 from a random 5% sample of US Medicare enrollees. By selecting codes used for diagnoses and treatment, we identified 7174 cases of PE and 8923 cases of DVT. These cohorts were analyzed to provide incidence by age, race, sex, and geographic location; frequency of invasive treatment; frequency of PE after treatment for DVT; frequency of recurrence of PE; and survival after diagnosis.
RESULTS: Annual incidence rates per 1000 at age 65 to 69 years for PE and DVT were 1.3 and 1.8, respectively. Both rates increased steadily with age to 2.8 and 3.1 by age 85 to 89 years. For PE, women had lower rates than men (adjusted relative risk, 0.86; 95% confidence interval, 0.82 to 0.90), and blacks had higher rates than whites (adjusted relative risk, 1.25; 95% confidence interval, 1.15 to 1.36). For DVT, the associations with gender and race were weaker and in the opposite direction. Pulmonary embolectomy was done in 0.2% of cases of PE; interruption of the vena cava was done in 4.4% of cases of PE and in 2% of cases of DVT. Thrombectomy was done in 0.3% of all cases. Pulmonary embolism occurred in 1.7% of patients with DVT within 1 year of hospital discharge for initial treatment. The 1-year recurrence rate for PE was 8.0%. In-hospital mortality associated with PE and DVT was 21% and 3%, respectively. One-year mortality was 39% and 21%, respectively.
CONCLUSIONS: Pulmonary embolism and DVT are common problems in the elderly. Both increase with age, but the effects of race and sex are small. Current treatment patterns appear to be effective in preventing both PE after DVT and recurrence of PE. Both are associated with substantial 1-year mortality, suggesting the need to understand the role of associated conditions as well as the indications for prophylaxis and the methods of treatment.

Entities:  

Mesh:

Year:  1994        PMID: 8154949

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  76 in total

Review 1.  Tolerability profile of SERMs.

Authors:  D Agnusdei; N Iori
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis.

Authors:  Muhammad Ali; Ashwin N Ananthakrishnan; Emily L McGinley; Kia Saeian
Journal:  Dig Dis Sci       Date:  2011-01-30       Impact factor: 3.199

3.  Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study.

Authors:  P L Lutsey; A E Prizment; A R Folsom
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

Review 4.  [Pulmonary embolism: clinical relevance, requirements for diagnostic and therapeutic strategies].

Authors:  F G Nowak; P Halbfass; E Hoffmann
Journal:  Radiologe       Date:  2007-08       Impact factor: 0.635

5.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

Review 6.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

7.  Poor Adherence to Risk Stratification Guidelines Results in Overuse of Venous Thromboembolism Prophylaxis in Hospitalized Older Adults.

Authors:  Juliessa M Pavon; Richard J Sloane; Carl F Pieper; Cathleen S Colón-Emeric; Harvey J Cohen; David Gallagher; Miriam C Morey; Midori McCarty; Thomas L Ortel; Susan N Hastings
Journal:  J Hosp Med       Date:  2018-02-06       Impact factor: 2.960

Review 8.  Healthcare disparities in critical illness.

Authors:  Graciela J Soto; Greg S Martin; Michelle Ng Gong
Journal:  Crit Care Med       Date:  2013-12       Impact factor: 7.598

9.  Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.

Authors:  Eric Pautas; Isabelle Gouin; Oliver Bellot; Jean-Paul Andreux; Virginie Siguret
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Korean guidelines for the prevention of venous thromboembolism.

Authors:  Soo-Mee Bang; Moon Ju Jang; Doyeun Oh; Yeo-Kyeoung Kim; In Ho Kim; Sung-Soo Yoon; Hwi-Joong Yoon; Chul-Soo Kim; Seonyang Park
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.